Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

Medulloblastoma is a highly malignant paediatric brain tumour classified into four biologically and clinically distinct molecular subgroups 1. The present clinical approach to medulloblastoma involves ...

Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in the Journal of Cancer Research and Clinical Oncology.

These subgroup analyses add to the existing evidence of bempedoic acid as an effective treatment for the reduction of cardiovascular risk. MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH ...

Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3,4 Transparent and comprehensive reporting of subgroup ...

You can find over one million groups to join on LinkedIn, the social media network for professionals. Topics vary from discussions about how to think creatively to learning something new such as ...